{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:29:00Z","timestamp":1790836140858,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2011,10,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To investigate the clinical characteristics and treatment outcome of patients with lymphocyte-depleted classical Hodgkin's lymphoma (LDCHL) compared with other histologic subtypes of Hodgkin's lymphoma (HL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>From a total of 12,155 evaluable patients with biopsy-proven HL treated within the German Hodgkin Study Group trials HD4 to HD15, 10,019 patients underwent central expert pathology review. Eighty-four patients with LDCHL (&lt; 1%) were identified and confirmed. The median follow-up time was 67 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with LDCHL, compared with patients with other histologic subtypes, presented more often with advanced disease (74% v 42%, respectively; P &lt; .001) and \u201cB\u201d symptoms (76% v 41%, respectively; P &lt; .001). Other risk factors were also more frequent in patients with LDCHL. Complete remission or unconfirmed complete remission was achieved in 82% of patients with LDCHL compared with 93% of patients with other HL subtypes (P &lt; .001), and more patients with LDCHL had progressive disease. At 5 years, progression-free survival (PFS) and overall survival (OS) were significantly lower in patients with LDCHL compared with patients with other HL subtypes (PFS, 71% v 85%, respectively; P &lt; .001; OS, 83% v 92%, respectively; P = .0018). However, when analyzing the subgroup of patients who underwent treatment with intensified or dose-dense bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, patients with LDCHL (n = 39) had similar outcomes when compared with patients with other subtypes of HL (n = 3,564; P = .61).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LDCHL has a different pattern from other HL subtypes with more clinical risk factors at initial diagnosis and significantly poorer prognosis. Patients with LDCHL should be treated with modern dose-intense treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2011.36.4703","type":"journal-article","created":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T06:45:09Z","timestamp":1315896309000},"page":"3914-3920","source":"Crossref","is-referenced-by-count":26,"title":["Lymphocyte-Depleted Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group"],"prefix":"10.1200","volume":"29","author":[{"given":"Beate","family":"Klimm","sequence":"first","affiliation":[{"name":"Beate Klimm, Dennis A. Eichenauer, Heinz Haverkamp, Volker Diehl, Michael Fuchs, Peter Borchmann, and Andreas Engert, German Hodgkin Study Group; Jeremy Franklin, University Hospital of Cologne, Cologne; and Harald Stein, Berlin Reference Center for Lymphoma and Hematopathology at the Pathodiagnostik Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Franklin","sequence":"additional","affiliation":[{"name":"Beate Klimm, Dennis A. Eichenauer, Heinz Haverkamp, Volker Diehl, Michael Fuchs, Peter Borchmann, and Andreas Engert, German Hodgkin Study Group; Jeremy Franklin, University Hospital of Cologne, Cologne; and Harald Stein, Berlin Reference Center for Lymphoma and Hematopathology at the Pathodiagnostik Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Stein","sequence":"additional","affiliation":[{"name":"Beate Klimm, Dennis A. Eichenauer, Heinz Haverkamp, Volker Diehl, Michael Fuchs, Peter Borchmann, and Andreas Engert, German Hodgkin Study Group; Jeremy Franklin, University Hospital of Cologne, Cologne; and Harald Stein, Berlin Reference Center for Lymphoma and Hematopathology at the Pathodiagnostik Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Eichenauer","sequence":"additional","affiliation":[{"name":"Beate Klimm, Dennis A. Eichenauer, Heinz Haverkamp, Volker Diehl, Michael Fuchs, Peter Borchmann, and Andreas Engert, German Hodgkin Study Group; Jeremy Franklin, University Hospital of Cologne, Cologne; and Harald Stein, Berlin Reference Center for Lymphoma and Hematopathology at the Pathodiagnostik Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Haverkamp","sequence":"additional","affiliation":[{"name":"Beate Klimm, Dennis A. Eichenauer, Heinz Haverkamp, Volker Diehl, Michael Fuchs, Peter Borchmann, and Andreas Engert, German Hodgkin Study Group; Jeremy Franklin, University Hospital of Cologne, Cologne; and Harald Stein, Berlin Reference Center for Lymphoma and Hematopathology at the Pathodiagnostik Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Diehl","sequence":"additional","affiliation":[{"name":"Beate Klimm, Dennis A. Eichenauer, Heinz Haverkamp, Volker Diehl, Michael Fuchs, Peter Borchmann, and Andreas Engert, German Hodgkin Study Group; Jeremy Franklin, University Hospital of Cologne, Cologne; and Harald Stein, Berlin Reference Center for Lymphoma and Hematopathology at the Pathodiagnostik Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Beate Klimm, Dennis A. Eichenauer, Heinz Haverkamp, Volker Diehl, Michael Fuchs, Peter Borchmann, and Andreas Engert, German Hodgkin Study Group; Jeremy Franklin, University Hospital of Cologne, Cologne; and Harald Stein, Berlin Reference Center for Lymphoma and Hematopathology at the Pathodiagnostik Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"Beate Klimm, Dennis A. Eichenauer, Heinz Haverkamp, Volker Diehl, Michael Fuchs, Peter Borchmann, and Andreas Engert, German Hodgkin Study Group; Jeremy Franklin, University Hospital of Cologne, Cologne; and Harald Stein, Berlin Reference Center for Lymphoma and Hematopathology at the Pathodiagnostik Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"Beate Klimm, Dennis A. Eichenauer, Heinz Haverkamp, Volker Diehl, Michael Fuchs, Peter Borchmann, and Andreas Engert, German Hodgkin Study Group; Jeremy Franklin, University Hospital of Cologne, Cologne; and Harald Stein, Berlin Reference Center for Lymphoma and Hematopathology at the Pathodiagnostik Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","volume-title":"WHO classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008","edition":"4"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.17.970"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8869"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.042"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.55.3.162"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902930488"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/13.S1.75"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21995"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2905"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.476"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh046"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.0482"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.023"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022473"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000067"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8018"},{"key":"B17","author":"Borchmann P","journal-title":"J Clin Oncol"},{"key":"B18","first-page":"V448","volume":"33","author":"Borchmann P","year":"2010","journal-title":"Onkologie"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.765.765"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.764.764"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"B22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"Cox DR","year":"1972","journal-title":"J R Stat Soc B"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-008-0683-9"},{"key":"B25","first-page":"645","volume":"66","author":"Miller TP","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.3.284"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800915)46:6<1503::AID-CNCR2820460635>3.0.CO;2-0"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90253-6"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900010303"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.4.1207.004k34_1207_1213"},{"key":"B31","first-page":"982","volume":"21","author":"Klimm B","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi023"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-253211"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2011.36.4703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T19:39:35Z","timestamp":1741635575000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2011.36.4703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,10]]},"references-count":33,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2011,10,10]]}},"alternative-id":["10.1200\/JCO.2011.36.4703"],"URL":"https:\/\/doi.org\/10.1200\/jco.2011.36.4703","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,10]]}}}